Stock listing
OTC:BIOQ BIOQUAL, Inc. Stock
Follow BIOQUAL, Inc. into a list and get an email when it puts out news.
Share price · OTC:BIOQ
$30.00 USD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $30.00 – $30.00 USDNov 20, 2026
- Volume
- 471 sharesNov 20, 2026
- Market cap
- $26.83M USDAt the close on Nov 20, 2026 · price × 894,416 shares outstanding
- 52-week range
- $30.00 – $38.51 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5,590 USDMedian day 0 shares · 38 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:BIOQ · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $30.00 | 0.00 | 0.0% | $30.00 | $30.00 | $30.00 | 471 | |
| $30.00 | -1.00 | -3.2% | $30.00 | $30.00 | $30.00 | 100 | |
| $31.00 | +0.36 | +1.2% | $31.00 | $31.00 | $31.00 | 100 | |
| $30.64 | 0.00 | 0.0% | $30.64 | $30.64 | $30.64 | 0 | |
| $30.64 | 0.00 | 0.0% | $30.64 | $30.64 | $30.64 | 0 | |
| $30.64 | -2.36 | -7.2% | $32.90 | $32.90 | $30.64 | 900 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 1,095 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 1,095 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 1,095 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 1,095 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 1,100 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 1,272 | |
| $33.00 | 0.00 | 0.0% | $33.00 | $33.00 | $33.00 | 0 | |
| $33.00 | +0.50 | +1.5% | $33.00 | $33.00 | $33.00 | 100 | |
| $32.50 | 0.00 | 0.0% | $32.50 | $32.50 | $32.50 | 0 | |
| $32.50 | 0.00 | 0.0% | $32.50 | $32.50 | $32.50 | 0 | |
| $32.50 | 0.00 | 0.0% | $32.50 | $32.50 | $32.50 | 0 | |
| $32.50 | 0.00 | 0.0% | $32.50 | $32.50 | $32.50 | 0 |
Splits
1 split · OTC:BIOQ · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-6 | Consolidation |
- Ticker
- OTC:BIOQ
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 22, 2026
BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2027
Latest news
BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2027
Oct 22, 2026
Closed $30.64 (0.0%) on Oct 22, 2026
CORRECTING and REPLACING BIOQUAL Presents Financial Results for Fiscal Year 2026
Sep 22, 2026
Closed $33.00 (0.0%) on Sep 22, 2026
BIOQUAL Presents Financial Results for Fiscal Year 2026
Sep 22, 2026
Closed $33.00 (0.0%) on Sep 22, 2026
BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2026
Apr 21, 2026
Closed $37.51 (0.0%) on Apr 21, 2026
BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026
Jan 22, 2026
Closed $38.50 (0.0%) on Jan 22, 2026
BIOQUAL, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 5 in the last 12 months · 50 in all · newest Oct 22, 2026 · oldest 2018
Valuation
EV/sales 1.1× against a median of 2.4×: 3rd lowest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Aug 31, 2026 · price Nov 20, 2026
- Enterprise value
- $42.28M USD
- P/E
- Loss
- EV/sales
- 1.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- 2.6%
- Operating margin
- −11.8%
- Net margin
- −11.0%
- Debt to equity
- 1.0×
- Beta vs S&P 500
- -0.01
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BIOQUAL, Inc. · OTC:BIOQ | US$26.83M | US$42.28M | n/a | 1.1× | n/a | 0.8× | −11.0% | 1.0× | -0.01 |
| Abingdon Health PLC · LSE:ABDX | US$28.10M | US$26.11M | n/a | 1.8× | n/a | 3.5× | −19.4% | 0.2× | n/a |
| MedMira Inc. · TSXV:MIR | US$26.91M | US$27.23M | n/a | 105× | n/a | n/a | −808.2% | n/a | 0.29 |
| Ikonisys SA · EURONEXT:ALIKO | US$26.75M | US$31.11M | n/a | 20.4× | n/a | 1.3× | −302.8% | 0.3× | n/a |
| Interpace Biosciences, Inc. · OTC:IDXG | US$26.56M | US$23.63M | 1.2× | 0.6× | 21.0× | 1.1× | 58.1% | 0.0× | -0.33 |
| Microbix Biosystems Inc. · TSX:MBX | US$26.27M | US$25.96M | n/a | 2.4× | n/a | 1.6× | −31.7% | 0.3× | 0.03 |
| Bioptic Inc. · TPEX:6850 | US$26.10M | US$22.55M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | n/a |
| genOway SA · EURONEXT:ALGEN | US$25.86M | US$38.95M | 25.4× | 1.7× | 8.7× | 1.1× | 4.4% | 0.7× | n/a |
| Orientbio, Inc. · KRX:002630 | US$25.17M | −US$3.29M | 14.6× | −0.1× | −0.8× | 0.5× | 8.1% | 0.0× | n/a |
| Genesystem Co., Ltd. · KRX:363250 | US$24.68M | US$22.48M | n/a | 29.8× | n/a | 2.8× | n/a | 0.2× | n/a |
| Clever Culture Systems Limited · ASX:CC5 | US$24.56M | US$25.41M | n/a | 8.3× | n/a | 4.9× | −48.4% | 0.4× | n/a |
| Median of the others | US$26.18M | US$25.68M | 14.6× | 2.4× | 8.7× | 1.6× | −25.5% | 0.2× | 0.03 |
Team and board
| Officer | Role |
|---|---|
| Chris Kirk | Chief Financial Officer |
| Hanne Andersen Elyard | President, Chief Scientific Officer |
| Mitch Franklin | Chief Operating Officer |
| Anthony Cook | Vice President of Veterinary Services |
| Jim Treece | Vice President of Operations |
| Swagata Kar | Vice President, Preclinical Models and Services |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Jan 22, 2026 | 0.0% |
| Q1 2026 | Sep 18, 2025 · Before open | 0.0% |
| Q3 2025 | Apr 21, 2025 · Before open | |
| Q2 2025 | Jan 21, 2025 · Before open | |
| Q1 2025 | Oct 22, 2024 · After close | |
| Q3 2024 | Apr 22, 2024 · After close | |
| Q2 2024 | Jan 23, 2024 · After close | |
| Q1 2024 | Oct 20, 2023 · Before open | |
| Q3 2023 | Apr 21, 2023 · After close | −7.3% |
| Q2 2023 | Jan 20, 2023 · After close |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | Oct 21, 2022 · After close | |
| Q3 2022 | Apr 21, 2022 · After close | −5.9% |
| Q2 2022 | Jan 21, 2022 · After close | −6.3% |
| Quarter to Aug 31, 2021 | Sep 17, 2021 | |
| Quarter to May 31, 2021 | Aug 31, 2021 | |
| Quarter to Feb 28, 2021 | Apr 21, 2021 | |
| Quarter to Nov 30, 2020 | Jan 22, 2021 | +1.8% |
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39.9M | 48.9M | 58.6M | 62.7M | 66.2M | 57.7M | 46.4M | 39.5M | 35.9M | 36.6M |
| Cost of revenue | 38.5M | 50.8M | 51.2M | 50.1M | 53.1M | 43.7M | 36.7M | 32.1M | 27.2M | 26.7M |
| Gross profit | 1.43M | -1.90M | 7.43M | 12.6M | 13.0M | 14.0M | 9.69M | 7.41M | 8.73M | 9.90M |
| Research and development | 541.0K | 806.0K | 1.11M | 828.8K | 1.13M | 331.5K | 331.5K | 334.0K | ||
| Selling, general and administrative | 7.45M | 7.54M | 6.47M | 5.42M | 4.37M | 3.83M | 3.45M | 3.36M | ||
| Operating income | -4.47M | -1.90M | -19.6K | 1.10M | 6.53M | 8.56M | 5.32M | 3.58M | 5.27M | 6.54M |
| Depreciation and amortization | 2.22M | 2.37M | 2.56M | 5.83M | 8.19M | 4.46M | 4.28M | 872.3K | 741.5K | 625.2K |
| EBITDA | -2.25M | 474.0K | 2.54M | 6.94M | 14.7M | 13.0M | 9.60M | 4.46M | 6.01M | 7.17M |
| Interest expense | 0 | 10.5K | 0 | 49.3K | 68.5K | |||||
| Income before tax | -3.72M | -1.29M | 476.4K | 1.13M | 6.58M | 8.62M | 5.49M | 3.71M | 5.29M | 6.49M |
| Income tax | 452.5K | -238.4K | -7.03K | 297.7K | 1.32M | 2.29M | 1.26M | 878.4K | 1.62M | 2.52M |
| Net income | -4.17M | -1.05M | 483.5K | 835.5K | 5.26M | 6.33M | 4.23M | 2.83M | 3.66M | 3.96M |
| Earnings per share, basic | -4.66 | -1.17 | 0.54 | 0.93 | 5.88 | 7.08 | 4.73 | 3.17 | 4.10 | 4.44 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 11.1M | 17.9M | 15.6M | 7.28M | 2.18M | 7.72M | 10.3M | 9.21M | 10.2M | 9.29M |
| Short-term investments | 4.89M | |||||||||
| Receivables | 10.5M | 13.2M | 14.0M | 21.3M | 26.8M | 20.1M | 14.6M | 11.5M | 9.69M | 8.35M |
| Inventory | 1 | 1 | 1 | 1 | 1 | |||||
| Current assets | 26.8M | 31.3M | 30.9M | 29.9M | 31.7M | 29.3M | 26.3M | 21.3M | 20.3M | 17.9M |
| Property, plant and equipment | 30.3M | 30.6M | 23.0M | 21.5M | 5.29M | 4.29M | 2.95M | |||
| Goodwill | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M |
| Total assets | 68.4M | 57.1M | 56.6M | 61.3M | 63.3M | 53.4M | 49.5M | 28.3M | 26.3M | 22.8M |
| Accounts payable | 1.04M | 1.90M | 1.38M | 1.59M | 3.29M | 2.11M | 2.48M | 1.31M | 1.80M | 1.24M |
| Current liabilities | 6.36M | 8.42M | 7.69M | 8.30M | 9.77M | 8.52M | 7.68M | 2.78M | 3.46M | 3.10M |
| Long-term debt | 250.1K | |||||||||
| Total debt | 32.7M | 16.5M | 3.59M | 18.6M | 18.7M | 14.6M | 16.1M | 250.1K | 567.3K | |
| Total liabilities | 36.0M | 21.0M | 18.9M | 23.7M | 25.7M | 19.9M | 21.4M | 3.75M | 4.26M | 3.84M |
| Shareholders' equity | 32.4M | 36.2M | 37.6M | 37.6M | 37.7M | 33.5M | 28.2M | 24.6M | 22.0M | 18.9M |
| Shares outstanding | 894.4K | 894.4K | 894.4K | 894.4K | 894.4K | 894.1K | 894.0K | 893.7K | 893.7K | 893.4K |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 351.4K | 2.94M | 9.36M | 8.23M | 313.4K | 2.15M | 4.08M | 1.70M | 3.71M | 5.39M |
| Capital spending | -418.2K | -238.8K | -597.1K | -2.24M | -4.89M | -4.41M | -2.40M | -1.87M | -2.07M | -741.8K |
| Free cash flow | -66.8K | 2.71M | 8.76M | 5.99M | -4.57M | -2.26M | 1.67M | -169.6K | 1.64M | 4.65M |
| Cash from investing | -7.08M | -238.8K | -597.1K | -2.24M | -4.73M | -3.70M | -2.40M | -1.86M | -1.98M | -578.5K |
| Cash from financing | -447.2K | -447.2K | -894.4K | -1.12M | -983.9K | -626.1K | -786.8K | -853.3K | -704.8K | |
| Dividends paid | -447.2K | -447.2K | -894.4K | -1.12M | -983.9K | -626.1K | -536.6K | -536.0K | -402.0K | |
| Change in cash | -6.73M | 2.26M | 8.31M | 5.10M | -5.54M | -2.54M | 1.05M | -953.0K | 872.2K | 4.11M |
Cap table
Built by 6ix from BIOQUAL, Inc.’s releases
- Common shares
- 894,416
- Fully diluted
- 894,416
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 894,416 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 894,416 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anthony Cook | Vice President of Veterinary Services · Since at least Nov 5, 2026 |
| Chris Kirk | Chief Financial Officer · Since at least Nov 4, 2026 |
| Hanne Andersen Elyard | President, Chief Scientific Officer · Since at least Apr 30, 2025 |
| Jim Treece | Vice President of Operations · Since at least Nov 4, 2026 |
| Mitch Franklin | Chief Operating Officer · Since at least Nov 4, 2026 |
| Swagata Kar | Vice President, Preclinical Models and Services · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about BIOQUAL, Inc.